Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-01-29

FDA Approved: BELSOMRA — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for BELSOMRA (suvorexant) submitted by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belsomra (suvorexant)

Snippet

SUPPL AP for BELSOMRA (SUVOREXANT)